Nissan Medical Industries Ltd (TLV:NISA)
Israel
· Delayed Price · Currency is ILS · Price in ILA 1,069.00
-10.00 (-0.94%)
Apr 1, 2025, 5:24 PM IDT
Nissan Medical Industries Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 664.08 | 733.91 | 684.65 | 668.37 | 721.48 | Upgrade
|
| Revenue Growth (YoY) | -9.52% | 7.20% | 2.44% | -7.36% | 19.16% | Upgrade
|
| Cost of Revenue | 566.06 | 598.14 | 601.37 | 523.95 | 540.03 | Upgrade
|
| Gross Profit | 98.02 | 135.78 | 83.28 | 144.42 | 181.45 | Upgrade
|
| Selling, General & Admin | 68.35 | 73.14 | 85.19 | 78.54 | 71.21 | Upgrade
|
| Other Operating Expenses | -0.01 | 1.26 | -0.15 | 0.07 | -0.1 | Upgrade
|
| Operating Expenses | 68.35 | 74.4 | 85.04 | 78.61 | 71.11 | Upgrade
|
| Operating Income | 29.68 | 61.37 | -1.77 | 65.81 | 110.34 | Upgrade
|
| Interest Expense | -17.8 | -21.27 | -10.02 | -7.28 | -9.39 | Upgrade
|
| Interest & Investment Income | - | 0.18 | 0.01 | - | 0.09 | Upgrade
|
| Earnings From Equity Investments | 1.3 | -7.06 | -0.64 | 4.62 | 10.66 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.55 | 0.05 | -8.33 | 3.19 | -1.06 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.43 | -5.47 | -2.44 | -1.28 | -1.3 | Upgrade
|
| EBT Excluding Unusual Items | 15.15 | 27.81 | -23.18 | 65.06 | 109.33 | Upgrade
|
| Impairment of Goodwill | - | - | -23.79 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0 | 0.01 | -0.05 | 5.39 | 0.68 | Upgrade
|
| Pretax Income | 15.15 | 27.82 | -47.02 | 70.45 | 110.01 | Upgrade
|
| Income Tax Expense | 1.35 | 8.78 | 0.27 | 13.29 | 17.12 | Upgrade
|
| Earnings From Continuing Operations | 13.8 | 19.04 | -47.29 | 57.16 | 92.89 | Upgrade
|
| Minority Interest in Earnings | -5.9 | -13.39 | 11.24 | -21.14 | -36.04 | Upgrade
|
| Net Income | 7.91 | 5.65 | -36.05 | 36.01 | 56.85 | Upgrade
|
| Net Income to Common | 7.91 | 5.65 | -36.05 | 36.01 | 56.85 | Upgrade
|
| Net Income Growth | 39.95% | - | - | -36.65% | 261.87% | Upgrade
|
| Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Change (YoY) | 0.04% | - | - | - | - | Upgrade
|
| EPS (Basic) | 0.87 | 0.62 | -3.97 | 3.96 | 6.26 | Upgrade
|
| EPS (Diluted) | 0.87 | 0.62 | -3.97 | 3.93 | 6.26 | Upgrade
|
| EPS Growth | 39.90% | - | - | -37.13% | 261.87% | Upgrade
|
| Free Cash Flow | 20.74 | 95.9 | 2.49 | 9.82 | 108.71 | Upgrade
|
| Free Cash Flow Per Share | 2.28 | 10.56 | 0.28 | 1.08 | 11.97 | Upgrade
|
| Dividend Per Share | - | - | - | 0.440 | 1.000 | Upgrade
|
| Dividend Growth | - | - | - | -56.00% | - | Upgrade
|
| Gross Margin | 14.76% | 18.50% | 12.16% | 21.61% | 25.15% | Upgrade
|
| Operating Margin | 4.47% | 8.36% | -0.26% | 9.85% | 15.29% | Upgrade
|
| Profit Margin | 1.19% | 0.77% | -5.27% | 5.39% | 7.88% | Upgrade
|
| Free Cash Flow Margin | 3.12% | 13.07% | 0.36% | 1.47% | 15.07% | Upgrade
|
| EBITDA | 59.32 | 86.9 | 22.25 | 91.4 | 137.76 | Upgrade
|
| EBITDA Margin | 8.93% | 11.84% | 3.25% | 13.68% | 19.09% | Upgrade
|
| D&A For EBITDA | 29.64 | 25.52 | 24.02 | 25.6 | 27.42 | Upgrade
|
| EBIT | 29.68 | 61.37 | -1.77 | 65.81 | 110.34 | Upgrade
|
| EBIT Margin | 4.47% | 8.36% | -0.26% | 9.85% | 15.29% | Upgrade
|
| Effective Tax Rate | 8.92% | 31.56% | - | 18.87% | 15.56% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.